期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 74, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2019.105688
关键词
Inunune repertoire; Next-generation sequencing; Immunotherapy; Cancer
资金
- Shanghai Science and Technology Development Funds [19QB1405900]
- Scientific Research Project of Jiading Health and Family Planning Commission [2018-QN-13]
With the prominent breakthrough in the field of tumor immunology, diverse cancer immunotherapies have attracted great attention in the last decade. The immune checkpoint inhibitors, adoptive cell therapies, and therapeutic cancer vaccines have already achieved impressive clinical success. However, the fact that only a small subset of patients with specific tumor types can benefit from these treatments limits the application of cancer immunotherapy. To seek out the molecular mechanisms behind this challenge and to select cancer precision medicine for different individuals, researchers apply the immune repertoire sequencing (IRS) to evaluate genetic responses of each patient to current immunotherapies. This review summarizes the technical advances and recent applications of IRS in cancer immunotherapy, indicates the limitations of this technique, and predicts future perspectives both in basic studies and clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据